These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 2880242)

  • 41. Extracorporeal immunoadsorption for the treatment of haemophilic patients with inhibitors to factor VIII or IX.
    Knöbl P; Derfler K
    Vox Sang; 1999; 77 Suppl 1():57-64. PubMed ID: 10529691
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Prospective matched control study concerning the treatment and quality of life of hemophiliacs with inhibitors].
    Honda K; Nagao T; Kamiya T; Yoshioka A; Miyazaki T; Takeda T; Mori K; Fukutake K; Hanabusa H; Taki M; Mohri H; Miyama J; Takamatsu J; Kinoshita S; Shirahata A
    Rinsho Ketsueki; 1998 Jun; 39(6):416-21. PubMed ID: 9695668
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Determination of the deficient factor in hemophilic patients].
    Peñaloza-Santillán JA; Arias y Arias J; Resano-Pérez F
    Bol Med Hosp Infant Mex; 1975; 32(1):51-9. PubMed ID: 1109289
    [No Abstract]   [Full Text] [Related]  

  • 44. [Inhibitors and "bypass" therapy in hemophilia].
    Fukutake K; Fukutake K
    Nihon Rinsho; 1981; 39(12):3688-99. PubMed ID: 6803034
    [No Abstract]   [Full Text] [Related]  

  • 45. Recent advances in the management of the child who has hemophilia.
    Dunn AL; Abshire TC
    Hematol Oncol Clin North Am; 2004 Dec; 18(6):1249-76, viii. PubMed ID: 15511615
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Hemophilia and HTLV-III infection].
    Lechler E
    Z Hautkr; 1986 Dec; 61(23):1687-704. PubMed ID: 2949442
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Fetal factor VIII and IX levels in early pregnancy and their significance in prenatal diagnosis.
    Fortune WA; Cox JR
    Acta Haematol; 1973; 49(5):314-7. PubMed ID: 4198913
    [No Abstract]   [Full Text] [Related]  

  • 48. Outbreaks of hepatitis A and emergence of new AIDS-associated agents: the need to add terminal 100 degrees C dry-heat sterilization to factor VIII and factor IX concentrates.
    Guillaume TA
    Vox Sang; 1993; 65(2):158. PubMed ID: 8212671
    [No Abstract]   [Full Text] [Related]  

  • 49. Clotting factor concentrates for resistant haemophilia.
    Bloom AL
    Br J Haematol; 1978 Sep; 40(1):21-7. PubMed ID: 361064
    [No Abstract]   [Full Text] [Related]  

  • 50. Zero incidence of inhibitors in previously untreated patients who received intermediate purity factor VIII concentrate or factor IX complex.
    Schimpf K; Schwarz P; Kunschak M
    Thromb Haemost; 1995 Mar; 73(3):553-5. PubMed ID: 7667845
    [No Abstract]   [Full Text] [Related]  

  • 51. Future characteristics of bypassing agents to improve care of hemophilia inhibitor patients: an economic and health-related quality of life perspective.
    Weatherall J; Barnes N; Brown C; Préaud E
    Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):411-4. PubMed ID: 21831021
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Treatment of hemophilia].
    Stavem P; Hjort PF
    Tidsskr Nor Laegeforen; 1970 Jul; 90(13):1413-8. PubMed ID: 5453192
    [No Abstract]   [Full Text] [Related]  

  • 53. [Transfusion problems in immunocoagulopathies].
    Lechner K; Stych H
    Bibl Haematol; 1971; 37():199-205. PubMed ID: 5138905
    [No Abstract]   [Full Text] [Related]  

  • 54. Treatment of hemophiliacs with inhibitors: cost and effect on blood resources.
    Aledort LM; Cohen M; Hilgartner M; Lipton R
    Prog Clin Biol Res; 1984; 150():353-65. PubMed ID: 6431439
    [No Abstract]   [Full Text] [Related]  

  • 55. [The 1st 2 cases of hemophilia in Senegalese children].
    Linhard J; Guicheney A; Plassart H; Diebolt G
    Bull Soc Med Afr Noire Lang Fr; 1967; 12(3):522-7. PubMed ID: 5598043
    [No Abstract]   [Full Text] [Related]  

  • 56. [Treatment of hemophiliacs with inhibitors].
    Fujimaki M
    Rinsho Ketsueki; 1985 Jul; 26(7):1059-68. PubMed ID: 3932719
    [No Abstract]   [Full Text] [Related]  

  • 57. Pioneering therapeutic proteins in hemophilia care through innovative technologies.
    Pabinger-Fasching I; Négrier C
    Thromb Res; 2016 May; 141 Suppl 3():S1. PubMed ID: 27288062
    [No Abstract]   [Full Text] [Related]  

  • 58. Haemophilia part 1: an introduction.
    Khair K
    Br J Nurs; 2013 Jun 13-26; 22(11):620. PubMed ID: 23899729
    [No Abstract]   [Full Text] [Related]  

  • 59. [Hemophilia].
    Shima M
    Rinsho Ketsueki; 2013 Feb; 54(2):189-97. PubMed ID: 23470826
    [No Abstract]   [Full Text] [Related]  

  • 60. Specific therapy in hemophilia.
    Hutaff LW
    N C Med J; 1973 Mar; 34(3):193-6. PubMed ID: 4510809
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.